Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label sequential dose escalation/de-escalation study of MT1002 in acute coronary syndrome patients undergoing PCI
CTR20232801Phase 2Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MT1002 in acute coronary syndrome (ACS), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Feb 2024; status: completed.
02
Drugs
MT1002
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on CTR20232801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232801.